On February 13, Allogene Therapeutics published new long-term follow-up data on cemacabtagene ansegedleucel, showing the investigative allogeneic chimeric antigen receptor (CAR) T-cell therapy ...

Dr. Bo Wiinberg, chief business development officer at the Novo Nordisk Foundation Cellerator, discusses the current ...

Regenerative medicine company Mesoblast Ltd. is preparing to launch its allogeneic bone marrow-derived mesenchymal stromal cell (MSC) therapy, Ryoncil, (remestemcel-L), in March in the U.S. and has ...

Losing around 50 to 100 hair strands in a day should not get you overly concerned. However, seeing more scalp than hair is ...

Background Treatment strategies for Crohn’s disease (CD) suppress diverse inflammatory pathways but many patients remain ...

A panel of 10 expert hematologists created recommendations for optimal MRD-guided ALL treatment, which were recently ...

Uday R. Popat, MD, discusses a phase 2 trial exploring the use of itacitinib combined with post-transplant cyclophosphamide and tacrolimus to prevent graft-vs-host disease in patients undergoing a ...

Many have had to live with lifelong suffering or seek expensive treatment abroad. But a groundbreaking medical revolution is changing that narrative in Uganda. Stem cell therapy, once considered ...

NLS Pharmaceutics Ltd. (Nasdaq: NLSP) ("NLS") and Kadimastem Ltd. (TASE: KDST) ("Kadimastem"), a clinical-stage company ...

Vor Biopharma's trem-cel offers hope for AML treatment, but financial risks and early-stage progress suggest caution. Learn ...